Spyre Therapeutics, Inc. (SYRE) — SC 13G/A Filings
All SC 13G/A filings from Spyre Therapeutics, Inc.. Browse 20 SC 13G/A reports with AI-powered summaries and risk analysis.
SC 13G/A Filings (20)
- SC 13G/A Filing — Nov 14, 2024
- SC 13G/A Filing — Nov 14, 2024
- SC 13G/A Filing — Nov 14, 2024
- SC 13G/A Filing — Nov 14, 2024
- SC 13G/A Filing — Nov 14, 2024
- SC 13G/A Filing — Nov 12, 2024
- SC 13G/A Filing — Jun 10, 2024
- SC 13G/A Filing — Apr 23, 2024
- SC 13G/A Filing — Mar 11, 2024
- SC 13G/A Filing — Feb 14, 2024
- SC 13G/A Filing — Feb 14, 2024
- SC 13G/A Filing — Feb 14, 2024
- SC 13G/A Filing — Feb 14, 2024
- SC 13G/A Filing — Feb 14, 2024
- SC 13G/A Filing — Feb 13, 2024
- SC 13G/A Filing — Feb 13, 2024
- SC 13G/A Filing — Feb 13, 2024
- SC 13G/A Filing — Feb 13, 2024
-
FMR LLC & Abigail Johnson Hold 13.065% Stake in Spyre Therapeutics
— Feb 12, 2024 Risk: low
FMR LLC, a major investment firm, and its principal owner, Abigail P. Johnson, have updated their ownership stake in Spyre Therapeutics, Inc. (formerly Aeglea B -
Millennium Management Amends Spyre Therapeutics Stake
— Feb 8, 2024 Risk: low
Millennium Management LLC and its affiliates, including Integrated Core Strategies (US) LLC, filed an amended Schedule 13G/A on February 8, 2024, disclosing the
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX